Reports Q1 revenue $79.41M, consensus $79.16M. “For the first quarter of 2025, I am pleased by our strong financial results, including total revenue of $79.4 million and Adjusted EBITDA of $6.3 million, with these results beating our quarterly guidance on each metric,” said Dan Burton, CEO of Health Catalyst (HCAT). “Additionally, we are happy to share that we added 10 net new Platform Clients in Q1 2025. This is especially encouraging given that Q1 is typically a quieter bookings quarter, and this performance gives us increased confidence of hitting our target of 40 net new Platform Client additions in 2025.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst announces strategic partnership with Microsoft
- Health Catalyst price target lowered to $6.50 from $7 at Citi
- Health Catalyst price target lowered to $5 from $7 at KeyBanc
- Health Catalyst downgraded to In Line from Outperform at Evercore ISI
- Health Catalyst: A Strategic Buy Amidst Promising Growth and Platform Potential
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue